Compounds that are inhibitors of the sodium channel and its use in the treatment of various disease States including Diabetes and cardiovascular disease. Pharmaceutical compositions containing the same.Claim 1: a compound of formula (1) wherein: Z is - - - - C (= nr u2074) - nr u00b2 - or - C = N - (nr u2075r u2076)； r u00b9 is cicloalquenilo, cycloalkyl, aryl, heteroaryl or heterociclilo； where the cicloalquenilo, cycloalkyl, aryl, heteroaryl or heterociclilo are optionally replaced with One, two, or three substituents selected from the group consisting of Halo Regardless, - CN, - no u2082,- sf u2085, IF (ch u2083) u2083 r u00b2 u2070, - O -, - S - r u00b2 u2070, r u00b2 u2070 - C (o) -, - C (o) - N - (or u00b2 u2070, r u00b2 u2070) (r u00b2 u00b2) - C (o) - N (r u00b2 u2070) (r u00b2 u00b2), - N (r u00b2 u2070) - C (o) - N - (r u00b2 u00b2, r u00b2 u2070) - C (o) - N - (or u00b2 u00b2, r u00b2 u2070) - S (= o) - O - r u00b2 u2076 u2082, u2082 r u00b2 u2070 (= o) -, - or - S - r u00b2 u2070 u2082 (= o) - S (= o) u2082 - n (r u00b2 u2070) (r u00b2 u00b2), alkyl c u2081 u208b u2086, alquenilo c u2082 u208b u2084, Alquinilo c u2082 u208b u2084, cycloalkyl, aryl, heteroaryl and heterociclilo； and where the c u2081 u208b u2086 alquenilo c u2082 u208b u2084, alkyl, cycloalkyl, aryl, alquinilo c u2082 u208b u2084,Heterociclilo are optionally substituted heteroaryl or with one, two or three substituents selected from the group consisting of independently - Halo, no u2082, heterociclilo heteroaryl phenyl, alkyl, cycloalkyl, c u2081 u208b u2086, - N (r u00b2 u2070) (r u00b2 u00b2), r u00b2 u2070 - C (o) -, - C (o) - C (or u00b2 u2070, - (O) n (R r u00b2 u2070) u00b2 u00b2), - CN, - or - r u00b2 u2070； R u00b2 c u2081 u208b u2086 is Hydrogen, alkyl, - C (o) - r u00b2 u2070, or u00b2 u2076 - C (o) -, - C (o) - N (r u00b2 u2076) (r u00b2 u2076), - N (r u00b2 u2070) - S (= o) - r u00b2 u2070 u2082,Cycloalkyl, aryl, heteroaryl or heterociclilo； where the c u2081 u208b u208
